Institutional & Family Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Institutional & Family Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-329	Closed	-$51K	–	1014
2020 Q4	$51K	Sell	329 -47	-13%	-$6.04K	0.01%	320
2020 Q3	$43K	Hold	376	–	–	0.01%	304
2020 Q2	$42K	Sell	376 -1,016	-73%	-$108K	0.01%	320
2020 Q1	$125K	Buy	1,392 +38	+3%	+$3.73K	0.03%	182
2019 Q4	$146K	Buy	1,354 +998	+280%	+$107K	0.03%	193
2019 Q3	$35K	Buy	356 +51	+17%	+$5.75K	0.01%	332
2019 Q2	$40K	Sell	305 -2	-0.7%	-$258	0.01%	336
2019 Q1	$42K	Buy	307 +87	+40%	+$10.8K	0.01%	342
2018 Q4	$21K	Sell	220 -50	-19%	-$5.91K	﹤0.01%	402
2018 Q3	$38K	Hold	270	–	–	0.01%	381
2018 Q2	$34K	Buy	270 +55	+26%	+$6.43K	0.01%	385
2018 Q1	$24K	Buy	+215	New	+$25.7K	0.01%	398

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Institutional & Family Asset Management's ALXN Position: Q1 2021 in Review

Institutional & Family Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 329 shares — an estimated $51K sold.

Institutional & Family Asset Management first reported a position in ALXN in Q1 2018 and held it in 12 quarters. The position peaked at $146K in Q4 2019. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Institutional & Family Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Institutional & Family Asset Management sold 329 Alexion Pharmaceuticals shares in Q1 2021, an estimated $51K.
Institutional & Family Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 12 quarters.
Institutional & Family Asset Management's Alexion Pharmaceuticals position peaked at $146K in Q4 2019.
753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Institutional & Family Asset Management's 13F filing for Q1 2021, filed 6 May 2021.